Small Molecule Metabolites as Predictors and Mediators of Immune Checkpoint Inhibitor Response

Information

  • Research Project
  • 9840822
  • ApplicationId
    9840822
  • Core Project Number
    F31CA236405
  • Full Project Number
    5F31CA236405-02
  • Serial Number
    236405
  • FOA Number
    PA-18-671
  • Sub Project Id
  • Project Start Date
    1/1/2019 - 6 years ago
  • Project End Date
    12/31/2021 - 3 years ago
  • Program Officer Name
    SCHMIDT, MICHAEL K
  • Budget Start Date
    1/1/2020 - 5 years ago
  • Budget End Date
    12/31/2020 - 4 years ago
  • Fiscal Year
    2020
  • Support Year
    02
  • Suffix
  • Award Notice Date
    12/31/2019 - 5 years ago

Small Molecule Metabolites as Predictors and Mediators of Immune Checkpoint Inhibitor Response

Project Summary: This application presents a 3-year predoctoral support structure for the training and research experience of the applicant, Mr. Ian Mathews, centered around identifying and characterizing small molecule mediators of cancer immunotherapy outcomes. Through a detailed training plan under sponsor Dr. Sonia Sharma and co-sponsor Dr. Mohit Jain, the applicant will pursue enrichment in human metabolomics, large scale biostatistics, tumor immunology, academic networking skills, and scientific rigor and ethics. Uniquely positioned between the University of California San Diego (Dr. Jain) and the La Jolla Institute for Allergy and Immunology (Dr. Sharma), this proposal interrogates a multidisciplinary academic niche. This highly specialized breadth of experiences, with dedicated guidance from both sponsor and co-sponsor, allows for the applicant?s enrichment as few other graduate student experiences can provide. Both mentors have a proven track record of collaboration and publication, a proven track record with academic trainees, and are resolutely dedicated to supporting the applicant in the pursuits of this proposal and his greater academic career. The applicant aims to 1) validate several newly identified predictive and dynamically regulated small molecule metabolites detected in biosamples from human immune checkpoint inhibitor patients; these metabolites strongly associate with the development of immune related adverse events (irAEs) in the patients, and 2) determine the functional role of these molecules in setting of deleterious chronic inflammation similar to the phentoypes of the patients. In pursuit of these goals, the applicant will utilize state-of-the-art, high throughput techniques in liquid chromatography-mass spectrometry (Jain), as well as novel, clinically relevant models of irAE inflammation and anti-tumor immunity (Sharma). Taken together, these training experiences, direct and fulfilling mentor relationships, and innovative research designs will serve as an invaluable foundation for the applicant?s future post-doctoral academic career.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    F31
  • Administering IC
    CA
  • Application Type
    5
  • Direct Cost Amount
    39220
  • Indirect Cost Amount
  • Total Cost
    39220
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    398
  • Ed Inst. Type
  • Funding ICs
    NCI:39220\
  • Funding Mechanism
    TRAINING, INDIVIDUAL
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    LA JOLLA INST FOR ALLERGY & IMMUNOLGY
  • Organization Department
  • Organization DUNS
    603880287
  • Organization City
    LA JOLLA
  • Organization State
    CA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    920371387
  • Organization District
    UNITED STATES